MX2023005301A - Compuestos dirigidos a brm y metodos de uso asociados. - Google Patents

Compuestos dirigidos a brm y metodos de uso asociados.

Info

Publication number
MX2023005301A
MX2023005301A MX2023005301A MX2023005301A MX2023005301A MX 2023005301 A MX2023005301 A MX 2023005301A MX 2023005301 A MX2023005301 A MX 2023005301A MX 2023005301 A MX2023005301 A MX 2023005301A MX 2023005301 A MX2023005301 A MX 2023005301A
Authority
MX
Mexico
Prior art keywords
associated methods
targeting compounds
brm
brm targeting
binding moiety
Prior art date
Application number
MX2023005301A
Other languages
English (en)
Spanish (es)
Inventor
Song Mei
Rupa Shetty
Andrew Paul Combs
Liang Lu
Chaofeng Dai
Klare Lazor Bersch
Corey Howard Basch
John A Rose
Danielle Julie Beam Roth
Original Assignee
Prelude Thereapeutics Incorporated
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Prelude Thereapeutics Incorporated filed Critical Prelude Thereapeutics Incorporated
Publication of MX2023005301A publication Critical patent/MX2023005301A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/12—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains three hetero rings
    • C07D487/14—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/454—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. pimozide, domperidone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/50—Pyridazines; Hydrogenated pyridazines
    • A61K31/5025—Pyridazines; Hydrogenated pyridazines ortho- or peri-condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
    • A61K47/55—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound the modifying agent being also a pharmacologically or therapeutically active agent, i.e. the entire conjugate being a codrug
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/12—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains three hetero rings
    • C07D471/14—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
MX2023005301A 2020-11-06 2021-11-08 Compuestos dirigidos a brm y metodos de uso asociados. MX2023005301A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US202063110688P 2020-11-06 2020-11-06
PCT/US2021/058424 WO2022099117A1 (en) 2020-11-06 2021-11-08 Brm targeting compounds and associated methods of use

Publications (1)

Publication Number Publication Date
MX2023005301A true MX2023005301A (es) 2023-07-18

Family

ID=81456756

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2023005301A MX2023005301A (es) 2020-11-06 2021-11-08 Compuestos dirigidos a brm y metodos de uso asociados.

Country Status (10)

Country Link
US (1) US12448389B2 (cg-RX-API-DMAC10.html)
EP (1) EP4240743A1 (cg-RX-API-DMAC10.html)
JP (1) JP2023549341A (cg-RX-API-DMAC10.html)
KR (1) KR20230117577A (cg-RX-API-DMAC10.html)
CN (1) CN116745295A (cg-RX-API-DMAC10.html)
AU (1) AU2021376415A1 (cg-RX-API-DMAC10.html)
CA (1) CA3200685A1 (cg-RX-API-DMAC10.html)
IL (1) IL302669A (cg-RX-API-DMAC10.html)
MX (1) MX2023005301A (cg-RX-API-DMAC10.html)
WO (1) WO2022099117A1 (cg-RX-API-DMAC10.html)

Families Citing this family (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PT4161935T (pt) * 2020-06-09 2025-08-14 Prelude Therapeutics Inc Compostos direcionados a brm e métodos de utilização associados
US20240024488A1 (en) * 2020-11-20 2024-01-25 Foghorn Therapeutics Inc. Compounds and uses thereof
CA3211347A1 (en) 2021-03-19 2022-09-22 Erika Araujo Indazole based compounds and associated methods of use
JP2024539269A (ja) * 2021-10-22 2024-10-28 グルータクス セラピューティクス (シャンハイ) カンパニー、リミテッド Crbn e3リガーゼリガンド化合物、当該リガンド化合物に基づいて開発したタンパク質分解剤及びそれらの応用
PL4245756T3 (pl) * 2022-03-17 2025-02-17 Gilead Sciences, Inc. Środki degradujące palec cynkowy z rodziny ikaros i ich zastosowania
JP2025521091A (ja) * 2022-05-10 2025-07-08 プレリュード・セラピューティクス・インコーポレイテッド がんの治療のためのsmarca4タンパク質分解因子としての6,6a,7,8,9,10-ヘキサヒドロ-5h-ピラジノ[1’,2’:4,5]ピラジノ[2,3-c]ピリダジン誘導体
EP4587127A1 (en) * 2022-09-15 2025-07-23 Prelude Therapeutics Incorporated Brm targeting compounds and associated methods of use
US20240190886A1 (en) * 2022-11-15 2024-06-13 Prelude Therapeutics Incorporated BRM Targeting Compounds and Associated Methods of Use
WO2024192064A1 (en) * 2023-03-14 2024-09-19 Oncopia Therapeutics, Inc. D/B/A/ Proteovant Therapeutics, Inc. Compounds and compositions as smarca2/4 degraders and uses thereof
CN120957992A (zh) * 2023-04-07 2025-11-14 南京再明医药有限公司 Brm选择性降解剂化合物
EP4695250A1 (en) 2023-04-12 2026-02-18 Aurigene Oncology Limited Tetracyclic compounds as smarca2 and/or smarca4 degraders
AU2024304006A1 (en) * 2023-06-16 2026-01-08 Plexium, Inc. Compounds and pharmaceutical compositions that degrade swi/snf-related matrix-associated actin-dependent regulator of chromatin subfamily a
AU2024352092A1 (en) 2023-09-28 2026-04-09 Arvinas Operations, Inc. Benzimidazole and benzimidazolone based protac compounds for the targeted degradation of leucine rich repeat kinase 2 (lrrk2)
WO2025101738A1 (en) * 2023-11-07 2025-05-15 Prelude Therapeutics Incorporated Brm targeting compounds and associated methods of use
WO2025106482A1 (en) * 2023-11-13 2025-05-22 Oncopia Therapeutics, Inc. D/B/A Sk Life Science Labs Compounds and compositions as smarca2/4 degraders and uses thereof
WO2025106472A1 (en) * 2023-11-13 2025-05-22 Regents Of The University Of Michigan Compounds and compositions as smarca2/4 degraders and uses thereof
WO2025113460A1 (zh) * 2023-11-28 2025-06-05 西藏海思科制药有限公司 一种哒嗪并三环衍生物及其在医药上的应用
AU2024411627A1 (en) * 2023-12-26 2026-07-16 Gluetacs Therapeutics (Shanghai) Co., Ltd. Compounds with two azaheterocycles substituted isoindolinone skeleton and uses thereof
WO2025184459A1 (en) * 2024-03-01 2025-09-04 Prelude Therapeutics Incorporated Brm and brg1 targeting compounds and associated methods of use
WO2025193454A1 (en) 2024-03-01 2025-09-18 Prelude Therapeutics Incorporated Brm and brg1 targeting antibody-drug conjugates and methods of use thereof
WO2025194405A1 (en) * 2024-03-21 2025-09-25 Prelude Therapeutics Incorporated Polymorphic smarca inhibitors and uses thereof
WO2026098598A1 (zh) * 2024-11-08 2026-05-15 正大天晴药业集团股份有限公司 含有三并杂环的化合物
WO2026136866A1 (en) 2024-12-20 2026-06-25 Prelude Therapeutics Incorporated Kat6 targeting compounds
WO2026151924A1 (en) * 2025-01-09 2026-07-16 Triana Biomedicines, Inc. 2-(2, 6-dioxopiperidine-3-yl)-1, 3-dioxoisoindoline derivatives bearing an heteroaryl group as anaplastic lymphoma kinase (alk) degraders and uses thereof

Family Cites Families (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3657744A (en) 1970-05-08 1972-04-25 Univ Minnesota Method for fixing prosthetic implants in a living body
US4733665C2 (en) 1985-11-07 2002-01-29 Expandable Grafts Partnership Expandable intraluminal graft and method and apparatus for implanting an expandable intraluminal graft
US5023252A (en) 1985-12-04 1991-06-11 Conrex Pharmaceutical Corporation Transdermal and trans-membrane delivery of drugs
US5040548A (en) 1989-06-01 1991-08-20 Yock Paul G Angioplasty mehtod
US5350395A (en) 1986-04-15 1994-09-27 Yock Paul G Angioplasty apparatus facilitating rapid exchanges
US5061273A (en) 1989-06-01 1991-10-29 Yock Paul G Angioplasty apparatus facilitating rapid exchanges
US4748982A (en) 1987-01-06 1988-06-07 Advanced Cardiovascular Systems, Inc. Reinforced balloon dilatation catheter with slitted exchange sleeve and method
US5001139A (en) 1987-06-12 1991-03-19 American Cyanamid Company Enchancers for the transdermal flux of nivadipine
US4992445A (en) 1987-06-12 1991-02-12 American Cyanamid Co. Transdermal delivery of pharmaceuticals
CA1322628C (en) 1988-10-04 1993-10-05 Richard A. Schatz Expandable intraluminal graft
US6344053B1 (en) 1993-12-22 2002-02-05 Medtronic Ave, Inc. Endovascular support device and method
US5674278A (en) 1989-08-24 1997-10-07 Arterial Vascular Engineering, Inc. Endovascular support device
US5292331A (en) 1989-08-24 1994-03-08 Applied Vascular Engineering, Inc. Endovascular support device
JP6815318B2 (ja) * 2014-12-23 2021-01-20 ダナ−ファーバー キャンサー インスティテュート,インコーポレイテッド 二官能性分子によって標的化タンパク質分解を誘導する方法
GB2554071A (en) 2016-09-14 2018-03-28 Univ Dundee Small molecules
SI3526202T1 (sl) 2016-10-11 2025-04-30 Arvinas Operations, Inc. Spojine in postopki za ciljno razgradnjo androgenskih receptorjev
IL266842B (en) 2016-12-01 2022-09-01 Arvinas Operations Inc History of tetrahydronaphthalene and tetrahydroisoquinoline as estrogen receptor antagonists
WO2019084026A1 (en) 2017-10-24 2019-05-02 Genentech, Inc. (4-HYDROXYPYRROLIDIN-2-YL) -HETEROCYCLIC COMPOUNDS AND METHODS OF USE
WO2019084030A1 (en) 2017-10-24 2019-05-02 Genentech, Inc. (4-HYDROXYPYRROLIDIN-2-YL) -HYDROXAMATE COMPOUNDS AND METHODS OF USE
AU2019249849C1 (en) 2018-04-01 2022-09-29 Arvinas Operations, Inc. BRM targeting compounds and associated methods of use
SG11202104495YA (en) * 2018-04-26 2021-05-28 Aurigene Discovery Tech Ltd Pyridazine derivatives as smarca2/4 degraders
WO2019213005A1 (en) * 2018-04-30 2019-11-07 Dana-Farber Cancer Institute, Inc. Small molecule degraders of polybromo-1 (pbrm1)
US12454520B2 (en) * 2018-07-06 2025-10-28 Kymera Therapeutics, Inc. Protein degraders and uses thereof
EP3867242A1 (en) 2018-10-15 2021-08-25 Nurix Therapeutics, Inc. Bifunctional compounds for degrading btk via ubiquitin proteosome pathway
WO2021133917A1 (en) * 2019-12-23 2021-07-01 Kymera Therapeutics, Inc. Smarca inhibitors and uses thereof
PT4161935T (pt) * 2020-06-09 2025-08-14 Prelude Therapeutics Inc Compostos direcionados a brm e métodos de utilização associados
JP2025521091A (ja) * 2022-05-10 2025-07-08 プレリュード・セラピューティクス・インコーポレイテッド がんの治療のためのsmarca4タンパク質分解因子としての6,6a,7,8,9,10-ヘキサヒドロ-5h-ピラジノ[1’,2’:4,5]ピラジノ[2,3-c]ピリダジン誘導体

Also Published As

Publication number Publication date
WO2022099117A1 (en) 2022-05-12
AU2021376415A9 (en) 2025-01-09
EP4240743A1 (en) 2023-09-13
CN116745295A (zh) 2023-09-12
CA3200685A1 (en) 2022-05-12
KR20230117577A (ko) 2023-08-08
IL302669A (en) 2023-07-01
AU2021376415A1 (en) 2023-06-22
JP2023549341A (ja) 2023-11-24
US12448389B2 (en) 2025-10-21
US20230083376A1 (en) 2023-03-16

Similar Documents

Publication Publication Date Title
AU2021289730A8 (en) BRM targeting compounds and associated methods of use
MX2025005722A (es) Compuestos dirigidos a brm y métodos de uso asociados
WO2019241430A3 (en) Antibody-oligonucleotide conjugates
CA3149406A1 (en) Novel anti-cldn18.2 antibodies
ZA202305221B (en) Tumor-specific claudin 18.2 antibody-drug conjugates
ZA202102696B (en) Anti-b7h3 antibody-exatecan analog conjugate and medicinal use thereof
MX2022011818A (es) Metodos y composiciones para el direccionamiento de canceres de celulas t.
EP3902839A4 (en) 18.2 CLAUDINE BINDING FRACTIONS AND THEIR USES
AU2018251801A8 (en) Novel type VI CRISPR orthologs and systems
EP4361261A3 (en) Novel cas13b orthologues crispr enzymes and systems
WO2023039424A3 (en) Methods and compositions for modulating a genome
WO2006028429A3 (en) Peptides for targeting the prostate specific membrane antigen
WO2015151078A3 (en) Hydrophilic linkers for conjugation
EP4414369A3 (en) Compounds and methods for the enhanced degradation of targeted proteins
EP4667565A3 (en) Methods and compositions for the treatment of fabry disease
WO2008112290A3 (en) Use of ephb4 as a diagnostic marker and a therapeutic target for ovarian cancer
WO2020260898A3 (en) Novel cancer antigens and methods
MX2024015476A (es) Compuestos dirigidos a kat6 con un resto de unión a ligasa de ubiquitina
WO2022232016A3 (en) Chimeric receptors targeting adgre2 and/or clec12a and uses thereof
WO2018187331A8 (en) Macrocyclic compound and uses thereof
MX2022015966A (es) Anticuerpos y metodos para tratar enfermedades asociadas a claudina.
WO2021262731A3 (en) Macrocyclic compounds and methods of use thereof
WO2021005338A3 (en) Novel cancer antigens and methods
EP4335496A3 (en) Phosphor(n)amidatacetal and phosph(on)atalcetal compounds
MX2022011779A (es) Combinacion herbicida.